Top Page
BeiGene Ltd
(6160)
BeiGene Ltd (6160) vs. iShares MSCI Hong Kong ETF (EWH)
BeiGene Ltd Business Overview & Revenue Model
BeiGene Ltd Earnings Call Summary
BeiGene Ltd Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.56B | 3.81B | 2.46B | 1.42B | 1.18B | 308.87M |
| Gross Profit | 3.90B | 3.22B | 2.08B | -511.06M | -447.86M | -1.06B |
| EBITDA | 89.25M | -396.44M | -1.12B | -1.72B | -1.39B | -1.63B |
| Net Income | -177.64M | -644.79M | -881.71M | -2.00B | -1.46B | -1.62B |
Balance Sheet | ||||||
| Total Assets | 6.30B | 5.92B | 5.81B | 6.38B | 8.65B | 5.60B |
| Cash, Cash Equivalents and Short-Term Investments | 2.76B | 2.63B | 3.17B | 4.53B | 6.62B | 4.65B |
| Total Debt | 1.03B | 1.08B | 930.18M | 596.67M | 694.64M | 561.96M |
| Total Liabilities | 2.53B | 2.59B | 2.27B | 2.00B | 2.40B | 1.73B |
| Stockholders Equity | 3.77B | 3.33B | 3.54B | 4.38B | 6.24B | 3.87B |
Cash Flow | ||||||
| Free Cash Flow | 164.84M | -669.77M | -1.75B | -1.97B | -1.61B | -1.51B |
| Operating Cash Flow | 571.21M | -140.63M | -1.16B | -1.50B | -1.30B | -1.28B |
| Investing Cash Flow | -416.03M | -548.35M | 60.00M | 1.08B | 640.66M | -3.17B |
| Financing Cash Flow | 9.39M | 193.45M | 416.48M | -18.97M | 3.64B | 5.20B |
BeiGene Ltd Technical Analysis
BeiGene Ltd Risk Analysis
BeiGene Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | HK$329.37B | 21.68 | 25.65% | 0.35% | 11.55% | 64.46% | |
| ― | $146.17B | 32.26 | 9.79% | ― | 16.90% | 63.11% | |
| ― | HK$210.60B | 40.06 | 16.09% | 1.07% | 8.68% | 0.82% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | HK$274.57B | ― | -4.94% | ― | 46.78% | 66.53% | |
| ― | $147.53B | 115.91 | 8.41% | ― | 52.78% | ― |
BeiGene Ltd Corporate Events
BeOne Medicines Ltd. has announced a series of waivers and exemptions from compliance with certain Hong Kong Stock Exchange Listing Rules and the Companies Ordinance. These include waivers related to the use of US GAAP, placings to connected persons, and collaboration agreements, among others. The company’s directors have taken responsibility for the accuracy of the information provided and have committed to updating the information sheet if there are material changes. This announcement highlights BeOne Medicines’ strategic moves to navigate regulatory requirements, potentially impacting its operational flexibility and stakeholder relations.
The most recent analyst rating on (HK:6160) stock is a Hold with a HK$186.00 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
BeOne Medicines Ltd., a Swiss corporation, announced it will release its unaudited financial results for the third quarter of 2025 on November 6, 2025, following the trading hours of the Hong Kong Stock Exchange. The results will be reviewed by the audit committee on the same day, and a conference call with management will be held to discuss the financials, providing stakeholders an opportunity to engage with the company’s leadership.
The most recent analyst rating on (HK:6160) stock is a Buy with a HK$236.00 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
BeOne Medicines Ltd., formerly known as BeiGene, Ltd., has officially changed its English company name and stock short name as part of its strategic rebranding efforts. The change, effective from May 27, 2025, reflects the company’s new identity and is confirmed by the Registrar of Companies in Hong Kong. The English stock short name for trading on the HKEX will be updated to ‘BEONE MEDICINES’ starting October 22, 2025, while the stock code remains ‘06160’. This rebranding is a significant step in the company’s evolution and may influence its market presence and stakeholder engagement.
The most recent analyst rating on (HK:6160) stock is a Buy with a HK$236.00 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
BeOne Medicines Ltd., a Swiss corporation, announced the grant of Restricted Share Units (RSUs) and Performance Share Units (PSUs) under its 2016 Share Option and Incentive Plan. On September 30, 2025, the company’s compensation committee granted 36,234 RSUs to 237 grantees and 2,935 PSUs to one grantee, representing approximately 0.03% of the total issued shares. This move is part of the company’s ongoing efforts to incentivize and retain talent, potentially impacting its operational dynamics and stakeholder interests positively.
The most recent analyst rating on (HK:6160) stock is a Buy with a HK$236.00 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
BeOne Medicines Ltd., a Swiss corporation, announced that Pharmacyclics LLC has decided not to appeal a decision by the U.S. Patent and Trademark Office, which invalidated all claims of a Pharmacyclics patent challenged by BeOne. This resolution, confirmed by a joint stipulation to dismiss related litigation, marks the end of the patent dispute, potentially strengthening BeOne’s position in the market.
The most recent analyst rating on (HK:6160) stock is a Buy with a HK$236.00 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
BeOne Medicines Ltd., a Swiss corporation, announced the completion of a share purchase under its 2018 Employee Share Purchase Plan (ESPP), allowing eligible employees to buy shares at a 15% discount. A total of 62,962 ADSs, representing 818,506 shares, were purchased by 3,932 participants, equating to approximately 0.05% of the total issued shares. The initiative aims to align employee interests with shareholders and retain talent without performance targets or clawback mechanisms, with 3,179,780 shares still available for future grants.
The most recent analyst rating on (HK:6160) stock is a Buy with a HK$236.00 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
BeiGene Ltd’s recent earnings call highlighted a strong performance, driven by significant revenue growth and advancements in research and development. The sentiment was overwhelmingly positive, despite challenges from competition and regulatory hurdles. The company’s achievements in market leadership and financial performance were emphasized, showcasing a robust outlook for the future.
BeOne Medicines Ltd. has announced a new offering period for its 2018 Employee Share Purchase Plan (ESPP), which allows eligible employees to purchase shares at a 15% discount to the market price. The offering period runs from September 2, 2025, to February 27, 2026, with 4,693 employees participating. This initiative is part of the company’s strategy to enhance employee engagement and align their interests with the company’s performance, although it does not include performance targets or a clawback mechanism.
The most recent analyst rating on (HK:6160) stock is a Hold with a HK$200.00 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
BeOne Medicines Ltd., a Swiss corporation listed on the Hong Kong Stock Exchange, has announced the grant of 36,510 Restricted Share Units (RSUs) to 202 employees under its 2016 Share Option and Incentive Plan. This grant represents approximately 0.03% of the company’s total issued shares. The RSUs are set to vest over four years, with no performance targets or clawback mechanisms attached, aligning with the company’s customary practices and market competitiveness. This move reflects the company’s strategy to incentivize its workforce while maintaining flexibility in its employee compensation structure.
The most recent analyst rating on (HK:6160) stock is a Hold with a HK$200.00 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
BeOne Medicines Ltd., a Swiss corporation, has announced positive topline results from a Phase 1/2 study of sonrotoclax, a next-generation investigational BCL2 inhibitor, for patients with relapsed or refractory mantle cell lymphoma (MCL). The study demonstrated clinically meaningful responses and a manageable safety profile, representing a significant milestone in BeOne’s hematology franchise. The company plans to submit the data to global regulatory bodies, including the U.S. FDA, for potential approval. This development could significantly impact the treatment landscape for MCL, offering new hope for patients with this aggressive disease.
The most recent analyst rating on (HK:6160) stock is a Hold with a HK$200.00 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
BeOne Medicines Ltd. reported a significant financial turnaround for the first half of 2025, with total revenues increasing by 44.7% to approximately US$2.43 billion compared to the same period in 2024. The company achieved a net income of US$95.6 million, a substantial improvement from a net loss of US$371.6 million in the previous year, driven by a notable rise in product revenue and controlled operating expenses.
The most recent analyst rating on (HK:6160) stock is a Hold with a HK$200.00 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
BeOne Medicines Ltd., a Swiss corporation, has announced a significant financial transaction involving the sale of royalty rights related to its monoclonal antibody product, Imdelltra, to Royalty Pharma Investments 2023 ICAV. The agreement involves an upfront payment of $885 million for a portion of the royalty rights, with an option for additional sales up to $65 million. This transaction is expected to have a material financial impact on BeOne’s operations, enhancing its financial position and potentially influencing its industry standing.
The most recent analyst rating on (HK:6160) stock is a Hold with a HK$200.00 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
BeOne Medicines Ltd. has announced that its audit committee will review and approve the interim results for the six months ended June 30, 2025, on August 28, 2025. These results, previously announced and filed with the SEC, will be published in accordance with the Hong Kong Listing Rules, including additional information and a reconciliation from U.S. GAAP to IFRS.
The most recent analyst rating on (HK:6160) stock is a Buy with a HK$156.80 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
BeOne Medicines Ltd., a corporation incorporated under the laws of Switzerland, announced the grant of Restricted Share Units (RSUs) under its 2016 Share Option and Incentive Plan. On August 8, 2025, the company’s compensation committee granted a total of 34,361 RSUs, representing 446,693 underlying shares, to 375 grantees. This grant accounts for approximately 0.03% of the total issued shares. The RSUs have a vesting period of four years, with 25% vesting annually, subject to continued employment. The announcement highlights the company’s commitment to incentivizing its workforce, potentially impacting employee retention and motivation.
The most recent analyst rating on (HK:6160) stock is a Buy with a HK$156.80 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
BeOne Medicines Ltd. announced the filing of its Form 10-Q for the quarterly period ending June 30, 2025, with the U.S. Securities and Exchange Commission. This regulatory announcement highlights the company’s compliance with reporting requirements, which is crucial for maintaining its listings on major stock exchanges and ensuring transparency for its stakeholders.
The most recent analyst rating on (HK:6160) stock is a Buy with a HK$148.40 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
BeOne Medicines Ltd., a corporation incorporated under the laws of Switzerland, has announced its unaudited financial results for the three and six months ended June 30, 2025. The results, prepared under U.S. GAAP, highlight key business updates and financial guidance for the full year 2025. The announcement underscores the company’s ongoing global expansion efforts and its commitment to bringing transformative medicines to patients worldwide. Stakeholders are advised to exercise caution regarding the financial guidance due to its preliminary nature and the inherent uncertainties.
The most recent analyst rating on (HK:6160) stock is a Buy with a HK$148.40 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.